Investor directory

HealthCare Ventures

HealthCare Ventures is a private equity and venture capital firm focused on life sciences and healthcare companies in North America. Established in 1985 and based in Cambridge, Massachusetts, with an additional office in Princeton, New Jersey, it invests across the seed, startup, early-stage, and growth spectrum, including mezzanine and bridge financings. The firm backs privately held biotechnology and life science companies developing products or platforms in areas such as targeted cancer therapies, cardiovascular and central nervous system diseases, infectious diseases, and immunomodulation or immunotherapy, as well as novel manufacturing technologies and lab-scale instruments. It seeks opportunities with broad technology platforms and late-stage products or novel innovations that could redefine medical practice and improve pharmaceutical manufacturing. Typical investments range from several million dollars to support company development in the United States.
http://www.hcven.com
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=20907
https://www.privateequityinternational.com/database/#/profile?id=6527

James H. Cavanaugh

Managing Director

Darren Heathcote

Managing Director

Gus Lawlor

Managing Director

John Littlechild

Managing Director and General Partner

Marla McMillan

Vice President of Finance

Past deals in New Jersey

VaxInnate

Series D in 2009
VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

VaxInnate

Series C in 2006
VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

VaxInnate

Series B in 2004
VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.